Argenx

OncoVerity is dedicated to enhancing the development of cusatuzumab, a novel anti-CD70 antibody, while also advancing medical research through its innovative platform. This platform focuses on creating clinical and single-cell multi-omics databases aimed at improving the lives of cancer patients. By bridging the gap between research and healthcare delivery, OncoVerity seeks to integrate advanced multi-omic data science into drug development. The company is committed to providing effective solutions for patients with unmet medical needs, ultimately aiming to deliver cutting-edge treatments to those battling cancer.

Priority Review voucher is an e-marketing application for efgartigimod.

OncoVerity is dedicated to enhancing the development of cusatuzumab, a novel anti-CD70 antibody, while also advancing medical research through its innovative platform. This platform focuses on creating clinical and single-cell multi-omics databases aimed at improving the lives of cancer patients. By bridging the gap between research and healthcare delivery, OncoVerity seeks to integrate advanced multi-omic data science into drug development. The company is committed to providing effective solutions for patients with unmet medical needs, ultimately aiming to deliver cutting-edge treatments to those battling cancer.

Halozyme Therapeutics, Inc. is a biotechnology company based in San Diego, California, specializing in the development and commercialization of innovative therapies that target the extracellular matrix, particularly through its proprietary ENHANZE drug delivery technology. This technology utilizes a patented recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of various injectable biologics and small molecules. Halozyme’s product portfolio includes Hylenex recombinant, which aids in fluid administration and enhances the absorption of injected drugs. The company is advancing a range of product candidates for conditions such as breast cancer, non-Hodgkin lymphoma, multiple sclerosis, and various autoimmune diseases. Additionally, Halozyme collaborates with major pharmaceutical companies to integrate its technology into therapeutic biologics. The company was founded in 1998 and operates internationally, primarily in the United States and Switzerland.